AUSTIN, Texas, Dec. 16, 2002 (PRIMEZONE) -- The following is an investment opinion issued by Stockwinners.com.
Concerns over profitability in the pharmaceutical sector are easing, the result of stabilizing earnings and corporate guidance. This has led to favorable performances by many of the drug calls featured in recent Stockwinners.com, http://www.STOCKWINNERS.com, Option Picks postings.
"In choosing our options, we concentrate on finding underlying equities with developing momentum," according to company spokesperson Faye F. Nia. "Among the options featured recently were Merck (NYSE:MRK) December $55 calls, up 259% in seventeen days, Cima Labs (Nasdaq:CIMA) December $25 calls, up 110% in ten days, and Teva Pharmaceutical Industries (Nasdaq:TEVA) December $37.50 calls, up 107% in fifteen days."
Overall, the recent Stockwinners.com options portfolio has more than doubled. In the three months ending December 13th, the independent research firm addressed the upward price potential of 256 publicly traded stock options. On average, the entire group was up 104% in eight days. The postings included one hundred fifty-seven calls and ninety-nine puts.
In addition to daily option picks, the service offers daily stock picks, a Rumor Mill, real-time quotes, intra-day market alerts via E-mail, pre-market/post-market prices, momentum plays and a continuously updated Active Traders page.
"In our Active Traders section, we provide technically rigorous analyses of major option transactions, throughout the trading day. Gains by many of the stock positions featured in that section were anticipated by high volume trading in options of the equities involved. Among the stock plays found that way was Amgen (Nasdaq:AMGN), up 14% in seven days."
Stockwinners.com may be reached at 800/946-7143. Free two-week on-line trial subscriptions to the service are available at http://www.stockwinners.com/info/first_time.html.
Stockwinners.com, Inc. is not a registered broker dealer or a registered investment adviser. No information accessed through the Stockwinners.com, Inc. Web site, or any link contained on the Stockwinners.com, Inc. Web site, constitutes a recommendation by Stockwinners.com, Inc. to buy, sell or hold any security, financial product, or instrument discussed therein. Information accessed through linked sites neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy or sell securities by Stockwinners.com, Inc. Stockwinners.com, Inc. may or may not hold positions in securities being discussed in this news release and/or mentioned on the Stockwinners.com, Inc. Web site. Investors shall be fully responsible for any investment decisions they make, and such decisions will be based solely on their evaluation of their financial circumstances, investment objectives, risk tolerance and liquidity needs. Investors are encouraged to consult with their registered broker and/or investment adviser before making any investment decision.